Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352367 | 0.89 | PPARD (0.64) | PPARDPPARA | |
| SCHEMBL2350620 | 0.89 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL2354034 | 0.89 | PPARD (0.83) | PPARDPPARA | |
| SCHEMBL2351142 | 0.85 | PPARD (0.64) | PPARDPPARA | |
| SCHEMBL27661973 | 0.84 | PPARD (0.73) | PPARDPPARA | |
| SCHEMBL2351149 | 0.84 | PPARD (0.60) | PPARDPPARA | |
| SCHEMBL3697254 | 0.83 | PPARD (0.80) | PPARDPPARA | |
| SCHEMBL941990 | 0.83 | PPARD (0.80) | PPARDPPARA | |
| SCHEMBL12083016 | 0.83 | PPARD (0.72) | PPARDPPARA | |
| SCHEMBL2351117 | 0.82 | PPARD (0.80) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243766-B1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids for use in treating PPAR-delta mediated conditions | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| EP-2243766-B1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids for use in treating PPAR-delta mediated conditions | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| US-8450371-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8450371-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-20120322875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2012-12-20 | — | — | US | disclosed |
| US-8258177-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-09-04 | — | — | US | disclosed |
| US-20110294875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
| US-20110294875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
| US-8008513-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-30 | — | — | US | disclosed |
| US-8008513-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-30 | — | — | US | disclosed |
| US-20100004470-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20100004470-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2010-01-07 | — | — | US | disclosed |
| US-7598292-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-06 | — | — | US | disclosed |
| US-7598292-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-06 | — | — | US | disclosed |
| EP-1670744-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACI DS AND ANALOGS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005030694-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20110294875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20100004470-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.